Focus: Nephron Pharmaceuticals is a CDMO and generic respiratory medication manufacturer founded in 1997, headquartered in West Columbia, SC. The company specializes in contract manufacturing and post-LOE generic inhalation products for respiratory and neurological conditions.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Growing — net +6 jobs in 30d
12 jobs added vs 6 removed. Steady team buildout.
Best suited for manufacturing, quality, and operations professionals seeking stable CDMO work; limited for those seeking R&D innovation, commercial strategy roles, or visibility into financial health.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Workhorse generic respiratory bronchodilator; multiple formulations indicate market penetration but no growth catalyst.
Help build intelligence for Nephron Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Nephron Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Anticholinergic COPD maintenance therapy; established safety profile but mature market with limited differentiation.
Combination therapy for COPD; represents formulary optimization of existing molecules with no novel mechanism.
NSAID analgesic outside core respiratory focus; diversifies portfolio but lacks growth indicators.
4 discontinued, 4 duplicate formulations not shown
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo